AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
This product will be manufactured at Lupin’s Nagpur facility in India
Subscribe To Our Newsletter & Stay Updated